Two arginine rich domains in the p14ARF tumour suppressor mediate nucleolar localization

被引:91
|
作者
Rizos, H [1 ]
Darmanian, AP [1 ]
Mann, GJ [1 ]
Kefford, RF [1 ]
机构
[1] Univ Sydney, Westmead Hosp, Westmead Inst Canc Res, Westmead, NSW 2145, Australia
基金
英国医学研究理事会;
关键词
p14ARF; nucleolar localization; hdm2; p53;
D O I
10.1038/sj.onc.1203629
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The INK4a/ARF locus encodes two distinct tumour suppressors, p16(INK4a) and p14ARF, that regulate cell cycle progression via the pRB and p53 pathways, respectively, The ARF protein inhibits hdm2 activity, leading to the stabilization of the p53 tumour suppressor and cell cycle inhibition, The amino-terminal domain of human p14ARF and of the mouse homologue, p19ARF, is sufficient for these effects, This domain is also sufficient for the nucleolar localization of the mouse ARF protein. In contrast, we show that the human ARF protein requires two arginine rich domains, one in the amino- and the other in the carboxy-terminus, for nucleolar targeting. The amino-terminal nucleolar-targeting domain of p14ARF is also important for ARF-hdm2 binding and cell cycle inhibition, The carboxy-terminal p14ARF nucleolar localization domain lies within the shared INK4a/ARF exon 2, and is mutated in a small number of melanoma-prone kindreds, The INK4a/ARF exon2-mutations could affect the function of both the p16(INK4a) and p14ARF tumour suppressors.
引用
收藏
页码:2978 / 2985
页数:8
相关论文
共 50 条
  • [21] Amino terminal hydrophobic import signals target the p14ARF tumor suppressor to the mitochondria
    Irvine, Mal
    Philipsz, Suzanah
    Frausto, Monika
    Mijatov, Branka
    Gallagher, Stuart J.
    Fung, Carina
    Becker, Therese M.
    Kefford, Richard F.
    Rizos, Helen
    CELL CYCLE, 2010, 9 (04) : 829 - 839
  • [22] Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus
    Watanabe, J
    Nishizaki, R
    Jobo, T
    Kamata, Y
    Hata, H
    Nishimura, Y
    Fujisawa, T
    Okayasu, I
    Kuramoto, H
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 2004, 23 (03) : 234 - 240
  • [23] Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I
    Ayrault Olivier
    Karayan Lucie
    Riou Jean-François
    Larsen Christian-Jacques
    Séité Paule
    Oncogene, 2003, 22 : 1945 - 1954
  • [24] Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2
    Clark, PA
    Llanos, S
    Peters, G
    ONCOGENE, 2002, 21 (29) : 4498 - 4507
  • [25] Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I
    Olivier, A
    Lucie, K
    Jean-François, R
    Christian-Jacques, L
    Paule, S
    ONCOGENE, 2003, 22 (13) : 1945 - 1954
  • [26] Multiple interacting domains contribute to p14ARF mediated inhibition of MDM2
    Paula A Clark
    Susana Llanos
    Gordon Peters
    Oncogene, 2002, 21 : 4498 - 4507
  • [27] Induction of apoptosis by the p14ARF tumour suppressor is fully independent of p53 and involves non-mitochondrial death pathways in colorectal cancer
    Overkamp, T.
    Mueer, A.
    Gillissen, B.
    Wendt, J.
    Doerken, B.
    Daniel, P.
    Hemmati, P.
    ONKOLOGIE, 2010, 33 : 225 - 225
  • [28] p16INK4A and p14ARF tumour suppressors in melanoma: lessons from the mouse
    Walker, GJ
    Hayward, NK
    LANCET, 2002, 359 (9300): : 7 - 8
  • [29] Helicobacter pylori pathogen regulates p14ARF tumor suppressor and autophagy in gastric epithelial cells
    Horvat, Andela
    Noto, Jennifer M.
    Ramatchandirin, Balamurugan
    Zaika, Elena
    Palrasu, Manikandan
    Wei, Jinxiong
    Schneider, Barbara G.
    El-Rifai, Wael
    Peek, Richard M., Jr.
    Zaika, Alexander I.
    ONCOGENE, 2018, 37 (37) : 5054 - 5065
  • [30] Role of the p14ARF tumor suppressor in EGFR-mediated growth control of bronchial adenocarcinoma
    Ozenne, P.
    Van den Broeck, A.
    Eymin, B.
    Perron, P.
    Barrial, C.
    Brambilla, C.
    Brambilla, E.
    Gazzeri, S.
    EJC SUPPLEMENTS, 2008, 6 (09): : 34 - 34